ATE327251T1 - Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen - Google Patents

Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen

Info

Publication number
ATE327251T1
ATE327251T1 AT00987364T AT00987364T ATE327251T1 AT E327251 T1 ATE327251 T1 AT E327251T1 AT 00987364 T AT00987364 T AT 00987364T AT 00987364 T AT00987364 T AT 00987364T AT E327251 T1 ATE327251 T1 AT E327251T1
Authority
AT
Austria
Prior art keywords
immunogenicity
amino acid
acid sequence
protein
peptide
Prior art date
Application number
AT00987364T
Other languages
English (en)
Inventor
Petronella Adriana M Warmerdam
Stephane Daniel Noee Plaisance
Desire Jose Collen
Maeyer Marc Cyriel Hilda De
Original Assignee
Thromb X N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thromb X N V filed Critical Thromb X N V
Application granted granted Critical
Publication of ATE327251T1 publication Critical patent/ATE327251T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00987364T 1999-12-02 2000-12-01 Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen ATE327251T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99204093 1999-12-02

Publications (1)

Publication Number Publication Date
ATE327251T1 true ATE327251T1 (de) 2006-06-15

Family

ID=8240963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00987364T ATE327251T1 (de) 1999-12-02 2000-12-01 Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen

Country Status (7)

Country Link
US (1) US20030134335A1 (de)
EP (1) EP1252183B1 (de)
CN (1) CN100335498C (de)
AT (1) ATE327251T1 (de)
AU (1) AU2363301A (de)
DE (1) DE60028248T2 (de)
WO (1) WO2001040281A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
ATE557034T1 (de) * 2001-11-13 2012-05-15 Danisco Us Inc Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen
US20040018568A1 (en) * 2002-07-23 2004-01-29 Subhashis Banerjee Methods for detecting deantigenized T cell epitopes and uses thereof
AU2004204942A1 (en) * 2003-01-08 2004-07-29 Xencor, Inc Novel proteins with altered immunogenicity
EP1638993A4 (de) * 2003-06-10 2007-05-09 Univ Melbourne Immunmodulierende zusammensetzungen, anwendungen davon und verfahren zu deren herstellung
US8452541B2 (en) * 2007-06-18 2013-05-28 Microsoft Corporation Vaccine design methodology
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
WO2009046742A1 (en) * 2007-10-09 2009-04-16 Thrombogenics N.V. Staphylokinase variant
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
EP2968450A4 (de) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modifizierte toxine
CN109002690B (zh) * 2018-06-08 2021-05-18 济南大学 通过构建charmm rotamers力场预测突变氨基酸侧链结构的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
EP1053330B1 (de) * 1998-02-04 2005-05-04 Thromb-X N.V. Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity

Also Published As

Publication number Publication date
WO2001040281A2 (en) 2001-06-07
WO2001040281A3 (en) 2001-12-20
US20030134335A1 (en) 2003-07-17
DE60028248D1 (de) 2006-06-29
AU2363301A (en) 2001-06-12
CN1414972A (zh) 2003-04-30
EP1252183B1 (de) 2006-05-24
EP1252183A2 (de) 2002-10-30
DE60028248T2 (de) 2007-03-15
CN100335498C (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
ATE454393T1 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
DE60028248D1 (de) Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen
CA2290485A1 (en) Method for the production of non-immunogenic proteins
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
RU2008120299A (ru) СПОСОБЫ ПОЛУЧЕНИЯ КОМПОЗИЦИЙ, ВКЛЮЧАЮЩИХ ХИТШОКОВЫЕ БЕЛКИ ИЛИ α-2-МАКРОГЛОБУЛИН, ПРИГОДНЫХ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ И ИНФЕКЦИОННОГО ЗАБОЛЕВАНИЯ
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
EA200401504A1 (ru) Слитый белок из числа регуляторных/вспомогательных белков вич
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
DE59509642D1 (de) Verfahren zur modifizierung der stabilität von antikörpern
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
RU2005106841A (ru) Эпитопы т-клеток в эритропоэтине
EP1104777A1 (de) Gelatin und ein Verfahren zu dessen Herstellung
ATE473755T1 (de) Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
ATE320603T1 (de) Methode zur identifizierung und eliminierung von t-zell epitopen
WO2002073209A3 (de) Verfahren zur identifikation von immunreaktiven epitopen auf proteinen
DE59005082D1 (de) Antikörper gegen hochkonservierte Aminosäuresequenzen von immunogenen Substanzen, Verfahren zur Herstellung dieser Antikörper, sowie deren Verwendung in Immunoassays.
EP1310512A3 (de) HCV-Kernprotein-Sequenzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties